Abstract:Key PointsMost human cancers exhibit a high degree of intratumour heterogeneity that arises from heritable and stochastic genetic and epigenetic changes, as well as environmental variations within the tumour. Heterogeneous subpopulations that exist within close proximity and compete for limited resources can engage in complex interactions that affect tumorigenesis, disease progression and therapeutic outcomes.Phenotypic changes that arise from subclonal interactions in heterogeneous tumours were observed by cancer biologists very early on. However, as studies mostly focused on cell-autonomous oncogenes and tumour suppressors, investigations into clonal interactions went under the radar for almost three decades. With the increasing recognition of intratumour heterogeneity fuelled by advances in technology, dissecting the mechanistic basis of clonal interactions is now gaining more attention.In addition to the more traditional models that explore clonal interactions strictly from the competitive angle, newer studies are investigating cooperative interactions among subclones that could give rise to novel characteristics and that potentially increase the growth and progression of the tumour.In the absence of proper tools to directly study clonal interactions in patient samples, studies in D. melanogaster, rodents and xenograft systems (using both established cell lines and patient-derived cells) are providing us with mechanistic insights into interclonal crosstalk.Theoretical and mathematical modelling are being used to simulate clonal dynamics under variable circumstances. Although currently far from perfect, these in silico cancer models have already been useful for the design of optimized cancer therapies for the more effective eradication of tumours.Cooperation can be metabolically costly but evolution and survival are more efficient, especially in a changing environment, when diversity and heterogeneity are high. Insights from patient tumours have revealed the presence of multiple independent neoplastic driver subclones that could re-establish tumour heterogeneity after therapy and lead to disease relapse. Furthermore, there is increasing evidence of transient clonal cooperation between neoplastic and benign subclones, which can also lead to tumour recurrence.In order to tackle the ever-evolving populations of tumour cells more effectively and to devise more lasting cures in patients, we must use ecological approaches that take advantage of cooperative tumour-promoting interactions and strategically eliminate them instead of targeting each individual subpopulation.

Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors

Disruption of metazoan gene regulatory networks in cancer alters the balance of co-expression between genes of unicellular and multicellular origins

The degenerative evolution from multicellularity to unicellularity during cancer

Neo-Darwinian Principles Exemplified in Cancer Genomics

Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution

Phylostratic Shift of Whole-Genome Duplications in Normal Mammalian Tissues towards Unicellularity Is Driven by Developmental Bivalent Genes and Reveals a Link to Cancer

Tumorigenesis: it takes a village

Evolutionary mechanism unifies the hallmarks of cancer

Characterizing the Ecological and Evolutionary Dynamics of Cancer

Beyond genetics: driving cancer with the tumour microenvironment behind the wheel

The origin of novel traits in cancer

Transcriptional signals of transformation in human cancer

Nongenetic evolution of the tumor: from challenges to new therapeutic opportunities

Hallmarks of Cancer: The Next Generation

Complex-based analysis of dysregulated cellular processes in cancer

Lineage Recording Reveals the Phylodynamics, Plasticity and Paths of Tumor Evolution

Gene networks reveal stem-cell state convergence during preneoplasia and progression to malignancy in multistage skin carcinogenesis

The Epigenetic Hallmarks of Cancer

AKT and the Hallmarks of Cancer

Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets

Cancer: Evolution Within a Lifetime